GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actelion Ltd (OTCPK:ALIOF) » Definitions » Research & Development

Actelion (Actelion) Research & Development : $587 Mil (TTM As of Mar. 2017)


View and export this data going back to . Start your Free Trial

What is Actelion Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Actelion's Research & Development for the three months ended in Mar. 2017 was $153 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2017 was $587 Mil.


Actelion Research & Development Historical Data

The historical data trend for Actelion's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actelion Research & Development Chart

Actelion Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 499.81 453.70 448.52 466.13 557.71

Actelion Quarterly Data
Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 142.16 142.26 125.93 165.38 152.97

Actelion Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $587 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Actelion  (OTCPK:ALIOF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Actelion Research & Development Related Terms

Thank you for viewing the detailed overview of Actelion's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Actelion (Actelion) Business Description

Traded in Other Exchanges
N/A
Address
Actelion is a Swiss biopharmaceutical firm with several products on the market, largely focused on pulmonary arterial hypertension: Tracleer, Opsumit, Uptravi, Ventavis, and Veletri treat various stages of the disease via different methods of administration. Zavesca is a second-line option for Gaucher disease, and Valchlor treats a rare form of blood cancer. Actelion has created a global commercial infrastructure for its approved orphan drugs and has supplemented its internal pipeline through in-licensing and acquisitions.

Actelion (Actelion) Headlines

From GuruFocus

Actelion Still On Growth Track

By reports.droy reports.droy 02-18-2015

Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary

By Holly LaFon Holly LaFon 02-14-2017

Jean Hynes Reduces Stake in Actelion

By Kyle Ferguson Kyle Ferguson 08-03-2016

Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary

By Holly LaFon Holly LaFon 01-24-2017